Cargando…

Statins and immune checkpoint inhibitors: a strategy to improve the efficacy of immunotherapy for cancer?

In the past decade, immune checkpoint inhibitor (ICI) therapy significantly improved the prognosis of patients with cancer. Despite impressive and often unprecedented response rates, a significant portion of the patients fails to benefit from this treatment. Additional strategies to improve ICI effi...

Descripción completa

Detalles Bibliográficos
Autores principales: Vos, Winnie G, Lutgens, Esther, Seijkens, Tom T P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9442479/
http://dx.doi.org/10.1136/jitc-2022-005611
_version_ 1784782821471027200
author Vos, Winnie G
Lutgens, Esther
Seijkens, Tom T P
author_facet Vos, Winnie G
Lutgens, Esther
Seijkens, Tom T P
author_sort Vos, Winnie G
collection PubMed
description In the past decade, immune checkpoint inhibitor (ICI) therapy significantly improved the prognosis of patients with cancer. Despite impressive and often unprecedented response rates, a significant portion of the patients fails to benefit from this treatment. Additional strategies to improve ICI efficacy are therefore needed. The widespread clinical use of ICIs has increased our knowledge on the effects of the concomitant use of commonly prescribed drugs on the outcome of ICI treatment. A particular interesting class of drugs in this context are statins. These HMG-CoA reductase inhibitors, which are used to treat hypercholesterolemia and reduce the risk for atherosclerotic cardiovascular disease, are frequently used by patients with (advanced) cancer. This paper addresses the hypothesis that statins improve the efficacy of ICI therapy.
format Online
Article
Text
id pubmed-9442479
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-94424792022-09-14 Statins and immune checkpoint inhibitors: a strategy to improve the efficacy of immunotherapy for cancer? Vos, Winnie G Lutgens, Esther Seijkens, Tom T P J Immunother Cancer Hypothesis In the past decade, immune checkpoint inhibitor (ICI) therapy significantly improved the prognosis of patients with cancer. Despite impressive and often unprecedented response rates, a significant portion of the patients fails to benefit from this treatment. Additional strategies to improve ICI efficacy are therefore needed. The widespread clinical use of ICIs has increased our knowledge on the effects of the concomitant use of commonly prescribed drugs on the outcome of ICI treatment. A particular interesting class of drugs in this context are statins. These HMG-CoA reductase inhibitors, which are used to treat hypercholesterolemia and reduce the risk for atherosclerotic cardiovascular disease, are frequently used by patients with (advanced) cancer. This paper addresses the hypothesis that statins improve the efficacy of ICI therapy. BMJ Publishing Group 2022-09-02 /pmc/articles/PMC9442479/ http://dx.doi.org/10.1136/jitc-2022-005611 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Hypothesis
Vos, Winnie G
Lutgens, Esther
Seijkens, Tom T P
Statins and immune checkpoint inhibitors: a strategy to improve the efficacy of immunotherapy for cancer?
title Statins and immune checkpoint inhibitors: a strategy to improve the efficacy of immunotherapy for cancer?
title_full Statins and immune checkpoint inhibitors: a strategy to improve the efficacy of immunotherapy for cancer?
title_fullStr Statins and immune checkpoint inhibitors: a strategy to improve the efficacy of immunotherapy for cancer?
title_full_unstemmed Statins and immune checkpoint inhibitors: a strategy to improve the efficacy of immunotherapy for cancer?
title_short Statins and immune checkpoint inhibitors: a strategy to improve the efficacy of immunotherapy for cancer?
title_sort statins and immune checkpoint inhibitors: a strategy to improve the efficacy of immunotherapy for cancer?
topic Hypothesis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9442479/
http://dx.doi.org/10.1136/jitc-2022-005611
work_keys_str_mv AT voswinnieg statinsandimmunecheckpointinhibitorsastrategytoimprovetheefficacyofimmunotherapyforcancer
AT lutgensesther statinsandimmunecheckpointinhibitorsastrategytoimprovetheefficacyofimmunotherapyforcancer
AT seijkenstomtp statinsandimmunecheckpointinhibitorsastrategytoimprovetheefficacyofimmunotherapyforcancer